JP2018516935A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516935A5 JP2018516935A5 JP2017562758A JP2017562758A JP2018516935A5 JP 2018516935 A5 JP2018516935 A5 JP 2018516935A5 JP 2017562758 A JP2017562758 A JP 2017562758A JP 2017562758 A JP2017562758 A JP 2017562758A JP 2018516935 A5 JP2018516935 A5 JP 2018516935A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- lymphoma
- acceptable salt
- cell
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- -1 1- (but-2-ynoyl) piperidin-3-yl Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical group OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 208000007465 Giant cell arteritis Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 206010043207 temporal arteritis Diseases 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- KOEUOFPEZFUWRF-LJQANCHMSA-N 4-amino-3-(4-phenoxyphenyl)-1-[(3R)-1-prop-2-enoylpiperidin-3-yl]imidazo[4,5-c]pyridin-2-one Chemical compound C(C=C)(=O)N1C[C@@H](CCC1)N1C(N(C=2C(=NC=CC=21)N)C1=CC=C(C=C1)OC1=CC=CC=C1)=O KOEUOFPEZFUWRF-LJQANCHMSA-N 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 206010018691 Granuloma Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- FPGGLMIYNLQOID-UHFFFAOYSA-N 3h-pyridin-2-one Chemical compound O=C1CC=CC=N1 FPGGLMIYNLQOID-UHFFFAOYSA-N 0.000 claims 1
- YMALYAHRSSETHN-IBGZPJMESA-N 4-amino-3-(4-phenoxyphenyl)-1-[[(2S)-1-prop-2-enoylpyrrolidin-2-yl]methyl]imidazo[4,5-c]pyridin-2-one Chemical compound C(C=C)(=O)N1[C@@H](CCC1)CN1C(N(C=2C(=NC=CC=21)N)C1=CC=C(C=C1)OC1=CC=CC=C1)=O YMALYAHRSSETHN-IBGZPJMESA-N 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 206010071578 autoimmune retinopathy Diseases 0.000 claims 1
- 210000000467 autonomic pathway Anatomy 0.000 claims 1
- 230000003376 axonal effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 125000004476 heterocycloamino group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002956 necrotizing effect Effects 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020001139A JP6985433B2 (ja) | 2015-06-03 | 2020-01-08 | チロシンキナーゼ阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170547P | 2015-06-03 | 2015-06-03 | |
| US62/170,547 | 2015-06-03 | ||
| US201562271689P | 2015-12-28 | 2015-12-28 | |
| US62/271,689 | 2015-12-28 | ||
| PCT/US2016/035588 WO2016196840A1 (en) | 2015-06-03 | 2016-06-02 | Tyrosine kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020001139A Division JP6985433B2 (ja) | 2015-06-03 | 2020-01-08 | チロシンキナーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516935A JP2018516935A (ja) | 2018-06-28 |
| JP2018516935A5 true JP2018516935A5 (cg-RX-API-DMAC7.html) | 2019-06-27 |
| JP6646072B2 JP6646072B2 (ja) | 2020-02-14 |
Family
ID=56118090
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562758A Active JP6646072B2 (ja) | 2015-06-03 | 2016-06-02 | チロシンキナーゼ阻害剤 |
| JP2020001139A Active JP6985433B2 (ja) | 2015-06-03 | 2020-01-08 | チロシンキナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020001139A Active JP6985433B2 (ja) | 2015-06-03 | 2020-01-08 | チロシンキナーゼ阻害剤 |
Country Status (33)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150044271A1 (en) | 2012-02-27 | 2015-02-12 | O-Ray Pharma, Inc. | Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders |
| BR112015003859B1 (pt) | 2012-09-10 | 2023-04-11 | Principia Biopharma Inc. | Composto e/ou sal farmaceuticamente aceitável do mesmo, respectivo uso e composição farmacêutica |
| JP6581506B2 (ja) | 2013-11-29 | 2019-09-25 | 株式会社ダイゾー | 内容物収容容器、それを用いた内容物収容製品、吐出製品および吐出装置 |
| CA2939186C (en) | 2014-02-21 | 2023-03-07 | Principia Biopharma Inc. | Salts and solid form of a btk inhibitor |
| ES2843323T3 (es) | 2014-12-18 | 2021-07-16 | Principia Biopharma Inc | Tratamiento de pénfigo |
| UA124090C2 (uk) * | 2015-06-03 | 2021-07-21 | Прінсіпіа Байофарма Інк. | Інгібітори тирозинкінази |
| WO2016210165A1 (en) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN105753863B (zh) * | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| WO2017066014A1 (en) | 2015-10-14 | 2017-04-20 | Sunnylife Pharma Inc. | Bruton's tyrosine kinase inhibitors |
| IL293621B2 (en) | 2016-06-29 | 2023-09-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile |
| JP6920411B2 (ja) * | 2016-07-25 | 2021-08-18 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | コリンキナーゼ阻害剤としてのプリン及び３−デアザプリンアナログ |
| EP3585789A1 (en) * | 2017-02-24 | 2020-01-01 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
| WO2019208805A1 (ja) * | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
| AU2019309727B2 (en) | 2018-07-25 | 2021-12-23 | Novartis Ag | NLRP3 inflammasome inhibitors |
| CA3224985C (en) | 2018-07-31 | 2025-11-18 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| US12077531B2 (en) * | 2018-09-13 | 2024-09-03 | Kissei Pharmaceutical Co., Ltd. | Imidazopyridinone compound |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| US20210106584A1 (en) | 2019-10-14 | 2021-04-15 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| CN113045484B (zh) * | 2019-12-27 | 2024-01-26 | 南京药石科技股份有限公司 | 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法 |
| CN113149891B (zh) * | 2020-01-07 | 2024-02-02 | 南京药石科技股份有限公司 | 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法 |
| KR20220130179A (ko) | 2020-01-20 | 2022-09-26 | 젠자임 코포레이션 | 재발성 다발성 경화증(rms)에 대한 치료용 티로신 키나제 저해제 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202140484A (zh) | 2020-01-22 | 2021-11-01 | 美商普林斯匹亞生物製藥公司 | ２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）－１Ｈ－吡唑并［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈之晶形 |
| MX2022012248A (es) * | 2020-03-30 | 2022-10-27 | Igia Pharmaceuticals Inc | Formulacion pediatrica de inhibidores de tirosina quinasa. |
| TW202214250A (zh) * | 2020-08-10 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｂｔｋ抑制劑治療疾病的用途 |
| CA3185469A1 (en) | 2020-08-14 | 2022-02-17 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
| CN116507627A (zh) | 2020-11-02 | 2023-07-28 | 勃林格殷格翰国际有限公司 | 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物 |
| JP2023553930A (ja) * | 2020-12-10 | 2023-12-26 | ジェンザイム・コーポレーション | トレブルチニブの結晶形態、その製造方法、およびその使用 |
| US20240051955A1 (en) * | 2020-12-23 | 2024-02-15 | Genzyme Corporation | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof |
| CN116710452A (zh) * | 2020-12-23 | 2023-09-05 | 建新公司 | 4-氨基-3-(4-苯氧基苯基)-1,3-二氢-2h-咪唑并[4,5-c]吡啶-2-酮衍生物及其盐类 |
| EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
| WO2022218430A1 (zh) * | 2021-04-16 | 2022-10-20 | 南京明德新药研发有限公司 | 咪唑并吡啶类化合物及其应用 |
| EP4328226A4 (en) * | 2021-04-23 | 2025-08-27 | Hangzhou Solipharma Co Ltd | CRYSTALLINE FORM, AMORPHOUS FORM OF TOLEBRUTINIB, PREPARATION PROCESS THEREOF AND USE THEREOF |
| EP4342468A4 (en) * | 2021-05-21 | 2025-06-04 | Hangzhou Solipharma Co., Ltd. | Tolbrutinib salt and crystal form thereof, manufacturing process therefor, pharmaceutical composition therefrom and use thereof |
| CA3221129A1 (en) | 2021-06-11 | 2022-12-15 | Minhua Chen | Crystal form of tolebrutinib, preparation method therefor and use thereof |
| WO2023280132A1 (zh) * | 2021-07-06 | 2023-01-12 | 苏州晶云药物科技股份有限公司 | 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法 |
| EP4404937A4 (en) * | 2021-09-24 | 2025-10-15 | Chadwick Donaldson | DRY POWDER FOAMING FORMULATIONS FOR DRUG DELIVERY ACROSS THE MUCOSA |
| US20250145618A1 (en) | 2021-12-21 | 2025-05-08 | Principia Biopharma Inc. | Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-YL)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and salts Thereof |
| WO2023172663A1 (en) * | 2022-03-09 | 2023-09-14 | Teva Pharmaceuticals International Gmbh | Solid state forms of tolebrutinib and of tolebrutinib salts |
| US20230399313A1 (en) * | 2022-06-10 | 2023-12-14 | Advenchen Pharmaceuticals, LLC | Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers |
| TW202408491A (zh) * | 2022-06-14 | 2024-03-01 | 美商健臻公司 | 製備托來布替尼的方法 |
| EP4543867A1 (en) * | 2022-06-22 | 2025-04-30 | Principia Biopharma Inc. | Methods of making modified btk inhibitors |
| TW202421141A (zh) | 2022-06-30 | 2024-06-01 | 美商健臻公司 | 用於多發性硬化症及重症肌無力之治療性酪胺酸激酶抑制劑 |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| US20240173313A1 (en) | 2022-10-11 | 2024-05-30 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for multiple sclerosis |
| CN118891260B (zh) * | 2022-11-07 | 2025-07-25 | 天津瑞程健达医药科技有限公司 | 氘代的氨基吡啶衍生物以及包含该化合物的药物组合物 |
| WO2024137604A1 (en) | 2022-12-20 | 2024-06-27 | Genzyme Corporation | Drug formulations of (r)-l-(l-acryloylpiperidin-3-yl)-4-amino-3-(4- phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one |
| AU2024214470A1 (en) | 2023-02-01 | 2025-09-11 | Principia Biopharma Inc. | Methods of diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid |
| US20250282777A1 (en) | 2024-03-06 | 2025-09-11 | Principia Biopharma Inc. | Methods of Making Tolebrutinib |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
| DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
| US3760984A (en) | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US3952741A (en) | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| WO2003037890A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Piperidines |
| US20060045822A1 (en) | 2004-09-01 | 2006-03-02 | Board Of Regents, The University Of Texas System | Plasma polymerization for encapsulating particles |
| EP1797091A2 (en) * | 2004-09-14 | 2007-06-20 | Novartis Vaccines and Diagnostics, Inc. | Imidazoquinoline compounds |
| JP2008530113A (ja) * | 2005-02-11 | 2008-08-07 | コーリー ファーマシューティカル グループ，インコーポレイテッド | オキシムおよびヒドロキシラミン置換イミダゾ［４，５−ｃ］環化合物および方法 |
| CA2653941C (en) | 2006-05-31 | 2013-01-08 | The Regents Of The University Of California | Substituted amino purine derivatives and uses thereof |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| NZ601278A (en) | 2006-09-22 | 2013-09-27 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| CN102713618B (zh) | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
| US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| BR112012030711B1 (pt) * | 2010-05-31 | 2020-10-13 | Ono Pharmaceutical Co. Ltd | derivado de purinona |
| WO2012158785A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
| ES2604191T3 (es) * | 2011-05-17 | 2017-03-03 | Principia Biopharma Inc. | Inhibidores de tirosina quinasas |
| MX355728B (es) * | 2011-05-17 | 2018-04-27 | Univ California | Inhibidores de cinasas. |
| BR112014012727B1 (pt) * | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| WO2013191965A1 (en) | 2012-06-18 | 2013-12-27 | Principia Biopharma Inc. | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
| CN109627239B (zh) | 2012-07-11 | 2021-10-12 | 缆图药品公司 | 成纤维细胞生长因子受体的抑制剂 |
| BR112015003859B1 (pt) * | 2012-09-10 | 2023-04-11 | Principia Biopharma Inc. | Composto e/ou sal farmaceuticamente aceitável do mesmo, respectivo uso e composição farmacêutica |
| US20140142099A1 (en) * | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| UA124090C2 (uk) * | 2015-06-03 | 2021-07-21 | Прінсіпіа Байофарма Інк. | Інгібітори тирозинкінази |
| CN105753863B (zh) | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| WO2017066014A1 (en) | 2015-10-14 | 2017-04-20 | Sunnylife Pharma Inc. | Bruton's tyrosine kinase inhibitors |
-
2016
- 2016-06-02 UA UAA201712794A patent/UA124090C2/uk unknown
- 2016-06-02 PH PH1/2021/551681A patent/PH12021551681A1/en unknown
- 2016-06-02 CN CN201680000891.8A patent/CN106459049B/zh active Active
- 2016-06-02 TW TW105117466A patent/TWI732765B/zh active
- 2016-06-02 TN TNP/2017/000501A patent/TN2017000501A1/en unknown
- 2016-06-02 HR HRP20211249TT patent/HRP20211249T1/hr unknown
- 2016-06-02 PH PH1/2017/502203A patent/PH12017502203B1/en unknown
- 2016-06-02 PL PL16728566T patent/PL3303334T3/pl unknown
- 2016-06-02 SI SI201631244T patent/SI3303334T1/sl unknown
- 2016-06-02 HU HUE16728566A patent/HUE055419T2/hu unknown
- 2016-06-02 DK DK16728566.7T patent/DK3303334T3/da active
- 2016-06-02 EP EP22188609.6A patent/EP4112618A1/en active Pending
- 2016-06-02 WO PCT/US2016/035588 patent/WO2016196840A1/en not_active Ceased
- 2016-06-02 MY MYPI2017704576A patent/MY190548A/en unknown
- 2016-06-02 ES ES16728566T patent/ES2878030T3/es active Active
- 2016-06-02 EP EP16728566.7A patent/EP3303334B1/en active Active
- 2016-06-02 KR KR1020247015612A patent/KR20240070721A/ko active Pending
- 2016-06-02 US US15/578,623 patent/US20180162861A1/en not_active Abandoned
- 2016-06-02 EP EP21169631.5A patent/EP3912979A1/en active Pending
- 2016-06-02 MX MX2021006571A patent/MX395007B/es unknown
- 2016-06-02 LT LTEPPCT/US2016/035588T patent/LT3303334T/lt unknown
- 2016-06-02 PT PT167285667T patent/PT3303334T/pt unknown
- 2016-06-02 KR KR1020227035399A patent/KR102666352B1/ko active Active
- 2016-06-02 CA CA2987335A patent/CA2987335A1/en active Pending
- 2016-06-02 CN CN202011284728.3A patent/CN113149983B/zh active Active
- 2016-06-02 PE PE2017002512A patent/PE20180521A1/es unknown
- 2016-06-02 KR KR1020177037609A patent/KR102552653B1/ko active Active
- 2016-06-02 SG SG10201912443XA patent/SG10201912443XA/en unknown
- 2016-06-02 RS RS20211083A patent/RS62290B1/sr unknown
- 2016-06-02 CR CR20170593A patent/CR20170593A/es unknown
- 2016-06-02 HK HK18111674.0A patent/HK1252378A1/zh unknown
- 2016-06-02 TW TW110121130A patent/TWI810582B/zh active
- 2016-06-02 JP JP2017562758A patent/JP6646072B2/ja active Active
- 2016-06-02 EA EA201792529A patent/EA039006B1/ru unknown
- 2016-06-02 MX MX2017015470A patent/MX383213B/es unknown
- 2016-06-02 AU AU2016270973A patent/AU2016270973B2/en active Active
-
2017
- 2017-01-19 US US15/410,716 patent/US9688676B2/en active Active
- 2017-11-27 IL IL255946A patent/IL255946A/en active IP Right Grant
- 2017-12-01 CL CL2017003073A patent/CL2017003073A1/es unknown
- 2017-12-01 DO DO2017000279A patent/DOP2017000279A/es unknown
- 2017-12-15 CO CONC2017/0012947A patent/CO2017012947A2/es unknown
- 2017-12-19 ZA ZA2017/08667A patent/ZA201708667B/en unknown
-
2019
- 2019-07-31 CL CL2019002150A patent/CL2019002150A1/es unknown
-
2020
- 2020-01-08 JP JP2020001139A patent/JP6985433B2/ja active Active
- 2020-05-26 AU AU2020203447A patent/AU2020203447B2/en active Active
- 2020-09-23 US US17/029,184 patent/US20210171526A1/en not_active Abandoned
- 2020-12-07 IL IL279258A patent/IL279258B/en unknown
-
2022
- 2022-10-27 US US17/974,613 patent/US20230151012A1/en not_active Abandoned
-
2024
- 2024-02-13 ZA ZA2024/01324A patent/ZA202401324B/en unknown
- 2024-11-26 US US18/960,997 patent/US20250197402A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516935A5 (cg-RX-API-DMAC7.html) | ||
| HRP20211249T1 (hr) | Inhibitori tirozin kinaze | |
| JP6776399B2 (ja) | ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用 | |
| AU2017383236B2 (en) | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | |
| CA2900855C (en) | Aminopyrimidinyl compounds | |
| CN108602827B (zh) | Bruton酪氨酸激酶的咪唑并吡嗪抑制剂 | |
| AU2013300106A1 (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| US20160039802A1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| JP2010501003A5 (cg-RX-API-DMAC7.html) | ||
| JP2011520896A5 (cg-RX-API-DMAC7.html) | ||
| JP2016525135A5 (cg-RX-API-DMAC7.html) | ||
| BR112015023142B1 (pt) | Moduladores do p2x7, seu uso, processo de preparação e composição farmacêutica que os compreende | |
| CA2759160A1 (en) | 3-azabicyclo [4.1.0] heptanes used as orexin antagonists | |
| RU2013143839A (ru) | Ингибиторы сериновых/треониновых киназ | |
| JP2016530338A5 (cg-RX-API-DMAC7.html) | ||
| JP2014509647A5 (cg-RX-API-DMAC7.html) | ||
| WO2014147586A1 (en) | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh | |
| JP2020529419A5 (cg-RX-API-DMAC7.html) | ||
| JP2016535042A5 (cg-RX-API-DMAC7.html) | ||
| JP2015535851A5 (cg-RX-API-DMAC7.html) | ||
| AU2018350980A1 (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors | |
| JP2013523814A5 (cg-RX-API-DMAC7.html) | ||
| HRP20220479T1 (hr) | Spojevi | |
| JP2018530582A5 (cg-RX-API-DMAC7.html) | ||
| MX2016016488A (es) | Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar). |